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Abstract
Many biologically important ligands of proteins are large, flexible, and often charged
molecules that bind to extended regions on the protein surface. It is infeasible or
expensive to locate such ligands on proteins with standard methods such as docking or
molecular dynamics (MD) simulation. The alternative approach proposed here is the
scanning of a spatial and angular grid around the protein with smaller fragments of
the large ligand. Energy values for complete grids can be computed efficiently with a
well-known Fast Fourier Transform accelerated algorithm and a physically meaningful
interaction model. We show that the approach can readily incorporate flexibility of
protein and ligand. The energy grids (EGs) resulting from the ligand fragment scans can
be transformed into probability distributions, and then directly compared to probability
distributions estimated from MD simulations and experimental structural data. We
test the approach on a diverse set of complexes between proteins and large, flexible
ligands, including a complex of Sonic Hedgehog protein and heparin, three heparin
sulfate substrates or non-substrates of an epimerase, a multi-branched supramolecular
ligand that stabilizes a protein-peptide complex, and a flexible zwitterionic ligand that
binds to a surface basin of a Kringle domain. In all cases the EG approach gives results
that are in good agreement with experimental data or MD simulations.
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Introduction
The prediction of binding poses of small molecules with a mixture of polar and hydropho-
bic groups that bind with high affinity in protein pockets has been one of the dominating
problems in biomolecular modeling, and the successes in this endeavor had a major impact
in the life sciences and drug design. However, many biologically important interactions are
almost the exact opposite to this scenario: large, flexible ligands bind to protein surfaces,
their binding is often transient, and charge-charge interactions are essential. Examples are
interactions between secreted proteins and the extracellular matrix of glycosaminoglycans,1,2
interactions of virus proteins with host receptors in viral cell entry,3 or interactions of T-cell
receptors with MHC I-peptide complexes.4 Another interesting case is the design of novel
supramolecular ligands that bind protein surfaces with many low affinity interactions but
overall high avidity.5 How can we model and predict complexes of proteins with such large,
flexible ligands that are often charged or zwitterionic? Sometimes it is possible to predict
binding modes of large, flexible ligands by docking suitable fragments with methods devel-
oped for small molecule docking.6 This is less promising if binding occurs not in typical small
molecule binding pockets, but at the protein surface, often involving charged residues with
long, flexible side chains, as for instance in the case of protein-glycosaminoglycan binding.
In these cases, interactions could be characterized by Molecular Dynamics simulation (MD)
or related sampling methods,7 though the necessary computational effort can be excessive.
A promising alternative are approaches that evaluate energies for ligand positions on
a 3D-grid around the target protein. Although they have mainly been used for docking,8
i.e. for locating optimal ligand positions and poses, they allow in principle for a characteriza-
tion of the complete target protein surface and environment with respect to ligand binding
energetics. A great advantage of grid-based approaches is that the protein-ligand interaction
energies on the grid can be evaluated efficiently by exploiting discrete Fast Fourier Trans-
forms (FFT).9–12 Since we are mostly interested in interactions of proteins with charged
ligands, another candidate method for characterizing the interaction energetics around the
target protein is the solution of the Poisson-Boltzmann equation, typically also with efficient
grid-based methods.13,14
In the work presented here we assess the suitability of fast grid-based methods for pre-
dicting binding modes of large, flexible, and usually charged ligands on protein surfaces.
These ligands not only defy docking methods, but they force us also to abandon the notion
of the well-defined binding pose, because their size and flexibility, and the fact that they
bind to extended protein surface regions will make binding more fuzzy.
One way to account for this uncertainty while still retaining a quantitative approach is
to predict affinity distributions or probability densities for the ligand, or at least for those
functional groups that likely mediate binding. The abovementioned grid-based methods9–12
are attractive because they could provide exactly this information in an efficient way. Gen-
erally, the approach proposed here assumes that we can infer the location of a large, flexible
ligand from probability distributions of characteristic fragments, and that these fragment
probability distributions can be computed efficiently and sufficiently accurate by grid based,
FFT accelerated scanning. We also demonstrate that flexibility of the target protein and of
ligand fragments can be incorporated easily.
To test the above assumptions we have applied the method to four different test cases
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that cover several scenarios of practical interest: the surface binding of heparin to Sonic
Hedgehog protein for which we compare several methods and experimental data, the specific
interactions of an epimerase with three different heparan sulfate substrates or non-substrates
as an example for specificity of interaction, the stabilization of a protein-peptide complex
by an artificial multi-branched supramolecular ligand as example of a large non-polymeric
ligand, and the binding of a flexible zwitterionic ligand to a Kringle domain.
Methods and molecules
Workflow
Figure 1: Workflow for the computation of (interaction) energy grids (EGs) with Epitopsy.
Representative conformations of ligand fragments and target protein are required as input
(A, B). Charges and radii of both interaction partners are assigned (C, D). The EG for a
ligand-protein pair as “correlation” with FFTs as described in text (E). EGs can then be
analyzed in various ways outside Epitopsy (F).
Figure 1 shows the overall workflow of our grid-based analysis. Each of the steps will
be described in the following section. To make our results reproducible we provide our
experimental Epitopsy software as free open source code at
https://github.com/BioinformaticsBiophysicsUDE/Epitopsy.
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Molecular dynamics (MD) simulation
MD simulations were used, first, to determine representative ligand conformations as input
of Epitopsy (Fig 1A), and second, as a reference method to estimate probability densities
of ligand fragments around the target protein that can then be compared to corresponding
probabilities computed from (interaction) energy grids (EGs) generated by Epitopsy.
Molecular Dynamics (MD) simulations were run with Gromacs 4.6.715 using the Amber
ff99SB force field16 for proteins and GLYCAM 06h-217 for saccharides. Phosphorylated
serine parameters were obtained from the literature.18 Non-standard amino acids in ligand
QQJ-096 (succinic acid, phenyl trihydrazine, N-acetyl-lysine and GCP) were parametrized
for the ff99SB force field according to the procedure described in the original ff94 article.19
Atomic charges were derived from electrostatic potential maps calculated at the HF/6-31**
level of theory in Gaussian09 version A.0220 and fitted to the residues using the Restrained
Electrostatic Potential method.21,22 Force constant parameters were obtained by chemical
analogy with readily available parameters in ff94.23 Topology files were created with the
pdb2gmx module of Gromacs for the protein, and with the TLEaP module of Amber v12.2124
with the AmberTools suite v13.22 for the ligands. Amber topologies were converted to
Gromacs topologies by ACPype.25
Proteins and ligands were solvated in a dodecahedron box of SPC/E water molecules26
with a 10 Å minimum separation between the protein and the box boundaries. The system
was neutralized by addition of Na+ and Cl− ions to a final ionic strength of 0.15 mol/l. The
system was energy-minimized by steepest-descent to a total force of 1800 kJmol−1 nm−1,
equilibrated for 5 ns in the NVT ensemble with constrained heavy atoms, and for 5 ns in the
NPT ensemble without constraints. Production simulation was run in the NPT ensemble
for 200 ns if not mentioned otherwise. Temperature was stabilized at 300 K in the NVT and
NPT ensembles by the V-rescale thermostat,27 while the pressure was stabilized at 1 atm in
the NPT ensemble by the Berendsen barostat (equilibration) or Parinello-Rahman barostat
(data production).28 Simulations were carried out on a GPU (GeForce 970 and GeForce
1070, CUDA 8) using a time step of 2 fs, the Verlet scheme29 for neighbor search with a
10 Å cutoff, the Particle Mesh Ewald method30 for electrostatic calculations, and the LINCS
algorithm31 for bond restraints.
Representative structures were extracted from trajectories based on mutual RMSDs,
using the g_rms tool in Gromacs to produce 2D RMSD plots, the pam (partition around
medoids) tool from R package cluster, version 2.0.6, in R v3.3.132 to find the clusters, and
the cluster.stats function of R package fpc, version 2.1.10, to validate the clustering based
on silhouette coefficients.
When high flexibility in the ligand prevented the extraction of representative structures,
the ligand trajectory was projected on a grid to produce a probability distribution of the
ligand around the protein. To this end, the simulation box was discretized and we counted
for each grid point the number of MD frames where it was within the van der Waals radius of
a ligand atom. The resulting count was divided either by the total number of frames in the
trajectory to yield a grid point sampling frequency, or by the sum of the grid point frequencies
to yield a (ligand) probability density. The latter was used to compute cumulative density
plots and to draw Highest Density Regions33 (HDR) in a molecular visualization software.
When comparing electrostatic, energy and probability density grids, all the compared grids
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were laid out with the same resolution, dimensions and offset.
EGs, HDR and molecules were visualized with PyMOL v1.7.4.034 compiled from sources.
Protein structures
Crystal structures were refined in Modeller 9.1735,36 to restore missing residues when nec-
essary (Table S2). Candidate structures were required to minimize the DOPE and molpdf
score. In case of ties, the refined model with lowest RMSD to the template was selected.
Assignment of charges and radii
For the computation of EGs, charges and radii have to be assigned to the ligand (Fig 1C)
and protein (Fig 1D). Charges and atomic radii were added on the proteins using PDB2PQR
v2.0.037,38 at neutral pH and 298 K using the Amber force field option. Ligand charges were
determined with one of the following methods, as specified in the text: with PDB2PQR
(default), specialized MM forcefields, from an electrostatic potential fit using the Merz-
Singh-Kollman scheme39,40 in Gaussian 2009 A0220 at the HF/6-31G** level of theory, or
using the Gasteiger-Marsili method41,42 in OpenBabel v2.3.2.43 Information on atomic radii
was added to the ligand atoms by OpenBabel.
Electrostatics
For the target protein the electrostatic field was computed by solving the non-linear Poisson-
Boltzmann equation with APBS version 1.4.114 at 310K, with an ionic concentration of
0.15 mol/l and relative dielectric permittivities εvacuumr = 2 and εwaterr = 79.
Energy grid computation
The central part of the workflow is the computation of the energy grid (EG) for a ligand
(or ligand fragment) and target protein (Figure 1E). As we are mainly interested in charged
ligands, the energy model currently only considers electrostatic interactions between ligand
and protein for non-overlapping relative positions and poses. EGs were calculated using the
EnergyGrid tool of Epitopsy 1.0.44 The following subsections we describe how the energy is
evaluated.
Shape complementarity
The atomic description of a protein – obtained either from experimentally solved structures
or from homology modeling – is mapped to a grid of dimensions (N1, N2, N3) with resolution
(m1,m2,m3), usually in the range 0.5–1.0 Å. The default value in this work was 0.8 Å.
Discretization proceeds by assigning a non-zero value to grid points within the van der Waals
radii defined by PDB2PQR for protein and ligand atoms. These discretized geometries are
labeled fvdwPl,m,n for the protein and f
vdw
Ll,m,n for the ligand:
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fvdwPl,m,n =

δ protein
+1 surface layer
0 water
fvdwLl,m,n =
{
+1 ligand
0 water
(1)
The surface layer is the ensemble of solvent grid points in direct contact with the protein.
The correlation is positive whenever the ligand is in contact with the protein surface (i.e. oc-
cupying the surface layer), negative when the ligand overlaps the protein, and zero otherwise.
Ligand poses with negative shape correlation are discarded. Flexibility is introduced by the
use of coefficients with opposite sign: an overlapping pose with n overlapping grid points
is rejected unless a minimum of |δ · n| grid points are in surface contact. We used mainly
δ = −15 as given by10 but point out in the discussion and Figure S3 that it can be useful to
vary δ.
The shape correlation fvdwCα,β,γ can be defined as the direct product of the two matrices
fvdwPl,m,n and f
vdw
Ll,m,n for any shift vector (α, β, γ):
fvdwCα,β,γ =
N1∑
l
N2∑
m
N3∑
n
fvdwPl,n,mf
vdw
Ll+α,n+β,m+γ (2)
This calculation has an asymptotic time complexity of O (n6), making it impractical for
solving numerically large systems. The Fast Fourier Transform (FFT) F (or F−1 for the
reverse operation) was successfully introduced by Gabb et al.10 in this context, resulting in
a time complexity of O (n3 ln (n3)):
FvdwP = F
{
fvdwPl,m,n
}
FvdwL = F
{
fvdwLl,m,n
}
FvdwC = F
vdw
P F
vdw
L
fvdwCα,β,γ = F−1
{
FvdwC
}
(3)
where the uppercase letter F represents the decomposed signal f , and F is the complex
conjugate of F .
Electrostatic energy
The electrostatic potential (ESP) Φl,m,n of the protein in ionic aqueous solution obtained by
solving the non-linear Poisson-Boltzmann equation (see above) is stored in a matrix ΦPl,m,n ,
with the protein interior and surface set to a potential of zero. The matrix qLl,m,n contains
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the ligand partial charges:
ΦPl,m,n =
{
0 protein
Φl,m,n water
qLl,m,n =
{
ql,m,n ligand
0 water
(4)
The electrostatic interaction between the ligand partial charges and the protein electro-
static potential is used to compute the energy correlation matrix f elecCα,β,γ :
f elecCα,β,γ =
N1∑
l
N2∑
m
N3∑
n
ΦPl,n,mqLl+α,n+β,m+γ (5)
The same FFT optimization described in Equation 3 is used to speed up the correlation
here:
FelecP = F
{
ΦPl,m,n
}
FelecL = F
{
qLl,m,n
}
FelecC = F
elec
P F
elec
L
f elecC = F−1
{
FelecC
} (6)
Correlation matrix
The energy correlation matrix f elecCα,β,γ (Equation 2) is the electrostatic contribution ∆E
elec
bind(α, β, γ)
to the binding affinity for any shift vector (α, β, γ) where the molecular probe does not over-
lap with the protein, i.e. for fvdwCα,β,γ ≥ 0:
∆Eelecbind(α, β, γ) = f
elec
Cα,β,γH
[
fvdwCα,β,γ
]
(7)
with Heaviside step operator
H[x] =
{
1, x ≥ 0,
0, x < 0
(8)
Angular sampling and energy grid values
The correlation matrices are evaluated for many orientations ω ∈ Ω of the ligand, where
Ω is a set of (φ, θ) tuples uniformly distributed on a sphere using a Fibonacci generative
spiral.45,46 The binding free energy ∆Gelecbind(α, β, γ) is computed from |Ω| correlations:
∆Gelecbind(α, β, γ,Ω) = −kBT ln

∑
ω∈Ω
exp
(
−f elecCωα,β,γH
[
fvdwCωα,β,γ
])
|Ω|
 (9)
The division by |Ω| accounts for the purely entropical free energy of the reference state,
i.e. the ligand immersed in pure solvent where it takes |Ω| orientations of zero enthalpy. We
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used mainly |Ω| = 150 as it provides a reasonable trade-off between accuracy and calculation
time; we show in Figure S2 the effect of increasing |Ω|.
The number of available ligand rotations at every grid point is
Ωavailable(α, β, γ,Ω) =
∑
ω∈Ω
H
[
fvdwCωα,β,γ
]
(10)
The ligand excluded volume (LEV) corresponds to the set of grid points α, β, γ where no
rotational state with finite energy is available to the ligand (Ωavailable = 0), or the set of all
grid points where function LEV is 1:
LEV(α, β, γ,Ω) = 1−H [Ωavailable − 1]
Energy grids for multiple conformers
When several conformers P of the protein and L of the ligand are provided, with respective
internal energies Ui for P and Uj for L, the binding free energy is:
∆Gelecbind(α, β, γ,P,L,Ω) = −kBT ln

∑
i∈P
e−Ui
∑
j∈L
e−Uj
∑
ω∈Ω
exp
(
−f elec
Cijωα,β,γ
H
[
fvdw
Cijωα,β,γ
])
|Ω| · ∑
i∈P
e−Ui
∑
j∈L
e−Uj

(11)
The number of available orientations is:
Ωavailable(α, β, γ,P,L,Ω) =
∑
i∈P
∑
j∈L
∑
ω∈Ω
H
[
fvdwCijωα,β,γ
]
(12)
Conversion to probability densities
EGs may be transformed into probability density functions (PDFs) with Boltzmann factors
K for positions outside the LEV:
K(α, β, γ) = (1− LEV(α, β, γ,Ω)) exp
(−∆Gelecbind(α, β, γ,Ω)
kBT
)
PDF(α, β, γ) =
K(α, β, γ)∑
K(α, β, γ)
(13)
Results
Sonic Hedgehog and heparin
The complex of Sonic Hedgehog protein (Shh) and a heparin ligand is prototypical for our
systems of interest: a large, flexible, and highly charged ligand binds to the surface of a
protein. The general assumption underlying our computational assessment of the heparin
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location is that we can infer the location of large, flexible ligands from the probability densi-
ties of characteristic fragments. Of course this assumption has to be tested, and it will break
down under certain conditions as we outline in the discussion. To test the approach we have
therefore compiled for this system a comprehensive data set, consisting of the electrostatic
potential (ESP) of Shh, energy grid (EG) for a di-saccharide heparin fragment scan of Shh,
seven 500 ns MD simulations of these di-saccharide fragments with Shh (sufficiently long to
observe ligand binding and unbinding events, Figure S7), and the crystal structure of the
Shh-heparin tetra-saccharide complex from.47
Overall, the four sources of data give a consistent picture (Figure 2): the ESP has its
largest high-potential region around Arg156, and this is where the EG has its largest low
energy blob, and where the heparin tetra-saccharide is located in the crystal structure, and
this is also the area of the highest heparin di-saccharide probability density, as estimated
from MD trajectories.
Assuming a Boltzmann distribution, the EG and ESP values can be transformed into
probability densities for ligand occupancy (Equation 13). This probability density can then
be compared directly with the probability density estimated by MD sampling, either visually,
e.g. with 3D-isosurfaces (Figure 2), or quantitatively (Figure 3). For the latter we evaluated
the frequencies with which the heparin di-saccharide visited each EG/ESP grid cube in the
concatenated MD trajectories as described in Methods. The highest probability density from
EG and MD is located in the same area around Arg156 (Figure 2C,D) where the EG shows
its by far largest low energy blob (Figure 2B). However, the EG probability density maximum
there has a much larger spatial spread than the MD probability density. Interestingly, the
region of 20% highest probability density as computed from heparin di-saccharide EGs forms
an envelope around the crystal position of the heparin tetra-saccharide, following the crystal
ligand in shape and size (Figure 2C). This supports our initial hypothesis that we can locate
larger ligands from probability distributions of fragments.
In a more quantitative comparison between EG and MD probability densities (Figure 3B)
we see that the MD probability density roughly follows an exponential of the EG values, as
expected for a Boltzmann distribution (coefficient of determination r2 = 0.93). The deviation
between the actual distribution and an exponential could be a result of unequilibrated MD
sampling or of EG model deficiencies.
The obvious similarity of ESP and EG (Figure 2A,B) suggests that ESP should have
a similarly good association with MD. However, this is not the case (Figure 3A). If we
transform ESPs into probability densities for a charged ligand, the probability density is
almost completely concentrated at a single grid point close to the two-calcium center of
Shh, 2 nm away from Arg156. While this point is certainly very attractive for the heparin
di-saccharide if we only consider Coulomb interactions, it is sterically not accessible and
therefore neither visible in the EG nor sampled by MD. Figure 3A suggests that the same is
true for many points of high ESP that are barely explored in MD simulations or evaluated
in the EG.
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C5-epimerase and poly-anionic heparan sulfate substrates and non-
substrates
D-glucuronyl C5-epimerase modifies heparan sulfate (HS), i.e. long, negatively charged, and
highly flexible carbohydrate chains. The epimerase has a varied surface topography with
deep clefts. The HS chains have to be threaded through a narrow, partially buried active
site, which makes the epimerase-HS complex a harder test case than the Shh-heparin complex
of the previous section, where heparin bound preferentially to a well-accessible surface patch
on Shh. The more specific, conformation dependent chemical function of the epimerase
suggests a more accurate positioning of the HS substrate chains on epimerase than the
superficial attachment of heparin to Shh. The hypothesis of a more accurate positioning
is consistent with the observed substrate length dependency of the reaction: enzymatic
activity decreased by 90% on a digested heparan sulfate fraction containing octasaccharides
and smaller oligosaccharides.48 Our question was therefore whether we would be able to
trace an extended binding site in EGs that could accommodate such longer oligosaccharides.
For validation we compared the predicted binding sites with crystallographically determined
binding sites with a heparin inhibitor (PDB entry 4pxq49).
We used three different HS dimer fragments (Figure 4A) to compute the EGs: CH3O--
GlcNS-GlcA-OCH3 as model of the substrate, CH3O-GlcNS-IdoA-OCH3 as model of the
product, and CH3O-GlcNAc-GlcA-OCH3 as a non-substrate.48,50 Note that in vitro the en-
zyme works both ways, i.e. the product is a substrate for the reversed reaction.50 A par-
simonious, natural explanation of this finding is that substrate and product use the same
molecular binding site.
In fact, in the EGs with epimerase substrate and product we detected the same low energy
channel, centered around the active sites (Figure 4B–D). The region that binds most strongly
in the EG matches the crystallographic positions of the heparin hexasaccharide, and covers
the amino acid residues most important for enzymatic activity.49 However, the low energy
Figure 2: Sonic Hedgehog protein (Shh) with heparin ligand. (A) ESP isosurfaces of Shh
at +1 kBT/|e| (blue) and −1 kBT/|e| (red). (B) EG isosurfaces at ±1 kBT (translucent
blue/red) and ±2 kBT (solid blue/red), merging across two population-weighted confor-
mations of a heparin di-saccharide (clustering details and glycosidic angles are provided
in Table S1) according to Equation 11. (C) EG based probability density of heparin di-
saccharide drawn around 20% HDR (solid green) and 30% HDR (translucent green). The
20% HDR forms a hull around the crystallographic position of the heparin tetra-saccharide
from47 (PDB entry 4c4n).(D) MD based probability density of heparin di-saccharide drawn
at 20% and 30% HDR (solid and translucent green) from a 3.5 µs multi-trajectory MD
simulation. (E) MD traces of the seven 500 ns simulations.
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Figure 3: Probability density of heparin di-saccharide occupancy computed from MD simu-
lations vs. electrostatic potential (A) and energy grid (B) at the same grid positions. Each
point in the plot stands for all grid points with a certain value of potential (A) or energy
(B), as given by its position along the horizontal axes. The number of grid points with the
respective ESP or EG values are shown as colors. Both horizontal axes go from repulsive
to attractive, and in both panels the vertical axes give the probability estimated by MD
sampling, averaged over the grid points with a given ESP or EG value. The error bars
mark the 99% confidence interval, assuming normally distributed probabilities. In panel A,
thirteen outliers in the ESP grid with energies ranging from 400 to 800 kBT/|e| lie outside
the plotting range. Figure S8 shows the distribution in a 2D histogram.
Figure 4: D-glucuronyl C5-epimerase interaction with heparan sulfate. (A) di-saccharides
used to compute EGs around epimerase. Top: substrate CH3O-GlcNS-GlcA-OCH3; middle:
product and in vitro substrate CH3O-GlcNS-IdoA-OCH3; bottom: non-substrate CH3O-
GlcNAc-GlcA-OCH3. (B) Crystal structure of epimerase in complex with heparin hexamer
(PDB entry 4pxq49). The two heparin fragments (black) bind at the two active sites of
the C2 symmetric enzyme dimer. Amino acids critical for reaction (Ala-mutations lead to
enzyme activity loss of >60% compared to wild-type49) are marked in blue. C–E: EGs of
substrate (C), product (D), and non-substrate (E) scanned using the apo protein (PDB
entry 4pw249) with isosurfaces drawn at −1 kBT (translucent red) and −2 kBT (solid red)
and crystallographic heparin (black space filling). Isosurfaces in C–E were robust against
changes of dihedral angles of the HS dimer used for scanning. Glycosidic angles are provided
in Table S1.
region extends noticeably beyond the crystallographic location of the heparin hexasaccharide
and could easily accommodate HS oligomers longer than octasaccharides (translucent red
in Figure 4C,D). The shape of this low energy region suggests a core binding site for HS
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chains reaching from the right flank of the narrow cleft with the active center down the
crystallographic heparin binding site.
While the substrate and product are both doubly negatively charged, the non-substrate
molecule (bottom of Figure 4A) carries only one negative charge. In the corresponding EG
the −1 kBT region has shrunk drastically and now only covers the location of the crystal-
lographic heparin hexasaccharide. Thus, although the non-substrate could be chemically
epimerized in principle – it has the same GlcA amenable to epimerization – this particular
epimerase enzyme offers no suitable binding site for a longer chain of this non-substrate type.
14-3-3 protein and poly-cationic supramolecular ligand
Recently we could demonstrate experimentally (Gigante et al., unpublished) that the binding
of a supramolecular ligand, QQJ-09651 (Figure 5B), stabilizes the interaction between the
14-3-3 protein and peptide fragments of c-Raf protein (we call this complex 14-3-3/c-Raf).
The large QQJ-096 ligand has three flexible arms (“R” in Figure 5B), each of them ending in
two positively charged groups, a Lysine and Guanidinocarbonylpyrrole (GCP). The size and
flexibility of the ligand makes it unsuitable for small molecule docking, and it is unlikely that
this ligand takes a single, well-defined binding pose. Nevertheless its effect on the interaction
of c-Raf and 14-3-3 could be explained most easily by a specific binding of QQJ-096 to 14-
3-3/c-Raf.
Figure 5: Interaction of 14-3-3/c-Raf complex with supramolecular ligand QQJ-096. (A)
isosurfaces of electrostatic potential at +1 kBT/|e| (blue) and −1 kBT/|e| (red) of 14-3-3/c-
Raf (PDB entry 4ihl52). (B) QQJ-096 ligand with only one of three arms (“R”) shown. (C)
GCP with capped ends. (D) Lys with capped ends. (E and F) EG computed with Epitopsy
for GCP and Lys, respectively, around 14-3-3/c-Raf. (G and H) 20% HDR (solid green) and
30% HDR (translucent green) for GCP and Lys, respectively, from a 1.5 µs multi-trajectory
MD simulation of the 14-3-3/c-Raf with QQJ-096 in aqueous solution.
The electrostatics of 14-3-3/c-Raf shows many of regions of low electrostatic potential
(red in Figure 5A) that could interact with the positive end groups of QQJ-096, Lys and
GCP. For a more ligand-specific assessment of binding, we computed two EGs with molecules
corresponding to the end groups of QQJ-096, GCP (Figure 5C) and Lys (Figure 5D). The
EGs show roughly the same features for GCP (Figure 5E) and Lys (Figure 5F), with par-
ticularly high affinities in the center of the 14-3-3 cleft between the c-Raf peptides. For Lys
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there are additional high affinity patches so that the c-Raf fragments are sandwiched be-
tween regions of high affinity of Lys. Both end groups have a few small high affinity islands
outside the central cleft of 14-3-3/c-Raf, with Lys having more of those islands than GCP.
Overall, this result suggests that QQJ-096 could seal off the 14-3-3/c-Raf cleft and in this
way inhibit dissociation of c-Raf fragments, in agreement with experimental results (Gigante
et al., unpublished).
For comparison we simulated the 14-3-3/c-Raf/QQJ-096 system with MD. Considering
the size of the molecular system and the low charge density on the ligand, a computational
experiment analogous to the Shh-heparin experiment above seemed to be unfeasible, i.e. we
do not expect to reach the MD steady state in the microsecond time scale with a ligand
initially positioned at random in the solvent box. Based on the experimental evidence for a
QQJ-096-mediated stabilization of the 14-3-3/c-Raf complex, and assuming a direct mode of
interaction, the MD starting conditions can be narrowed down to the 14-3-3 cleft (Figure S1).
Based on this reasoning, we carried out a pilot set of six 50 ns MD simulations of the 14-3-
3/c-Raf dimer in aqueous solution with QQJ-096 initially positioned 10 Å above the c-Raf
peptides. In three simulations the ligand failed to interact with the protein. We then ran
six 250 ns simulations with the ligand initially positioned 4–6 Å above the c-Raf peptides
and observed a quick convergence to binding sites of QQJ-096 end groups in the 14-3-3 cleft
matching those predicted by EGs computed with the end groups (Figure 5G,H). Regions
outside the cleft were barely explored. Thus, MD simulations and EGs both support the
same mechanism for the experimentally observed stabilization of the 14-3-3/c-Raf binding
by QQJ-096, namely that the supramolecular ligand QQJ-096 blocks the 14-3-3 cleft and in
this way impedes escape of c-Raf.
Kringle domain and flexible zwitterionic ligand
The Kringle domains of plasminogen attach to Lys residues on fibrin, a precondition for the
decomposition of fibrin by plasminogen. A known alternative ligand of the Kringle domains
is ε-aminocaproic acid (EACA), and a crystal structure of its complex with plasminogen
Kringle domain 4 (KR4) has been determined (PDB entry 2pk453). EACA is a highly
flexible, zwitterionic molecule (Figure 6A–C) that binds to a shallow basin in the KR4
surface. We have used the EACA-KR4 complex as a test case for the application of EGs
based on multiple ligand conformers for the identification of binding sites (Equation 11).
In an application scenario we would probably not know the actual conformer but rely on
plausible ligand conformers obtained from other experiments or modeling. Accordingly, our
EACA input conformers were the stretched conformer(Figure 6A) observed in the solid phase
of pure EACA,54 and a MM energy minimized turn geometry (Figure 6B) that is entropically
and enthalpically more favorable for a free ligand. The conformer actually observed in the
crystal complex (Figure 6C) is closer to the stretched geometry in the solid phase (Figure 6A),
though with a bent amino-end.
The zwitterionic nature of EACA suggests a binding site that bridges two regions of
opposite electrostatic potential. However, this pattern is too unspecific since there are many
regions that fall into this category (Figure 6D). The full correlation with shape and elec-
trostatics information leads to the identification of the correct binding basin, that, in fact,
bridges regions of opposite electrostatic potential (Figure 6E–G). For the stretched EACA
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conformer there are two binding sites, the one in the crystal structure, and an alterna-
tive binding site with slightly lower affinity between Asp381 and Lys433 (Figure 6E). For
the EACA turn conformer the correct basin is clearly the region with highest affinity (Fig-
ure 6F). The EG averaged over both ligand conformers (Equation 11, both ligand confor-
mations weighted equally) also has the basin of the crystal structure as clearly dominating
binding site (Figure 6G).
A question related to the multiconformer ligand treatment is the multiconformer receptor
treatment, and Equation 11 treats ligand and receptor symmetrical in this respect. In fact,
Figure 6G is based not only on two ligand conformations but also on three, equally weighted
KR4 receptor conformations, including the EACA-KR4 complex structure 2pk4, a KR4
complex with sulfate (PDB entry 1krn), and a KR4 complex with arginine (PDB entry
4duu). However, since the differences between receptor structures are small (RMSDs to
2pk4: 0.29 Å for 1krn and 0.69 Å for 4duu on Cα atoms) the results are very similar for the
combined EG and for the three EGs based on single receptor structures: For all three apo
KR4 structures the respective EG identified the same correct EACA binding basin as best
binding site.
Figure 6: ε-aminocaproic acid (EACA) and its complex with plasminogen Kringle domain 4
(KR4). (A) Experimental structure (“stretched”) of EACA in the solid phase (CCDC entry
110250954). B: Energy-minimized structure of EACA (“turn”, MMFF94 forcefield, steepest
descent in vacuum). (C) Structure of EACA in complex with KR4 (PDB entry 2pk4). (D)
Electrostatic potential isosurfaces around apo KR4 (PDB entry 2pk4) drawn at +1 kBT/|e|
(blue) and −1 kBT/|e| (red). E-G: EG isosurfaces a drawn at ±1 kBT (translucent blue/red)
and ±2 kBT (solid blue/red) of apo KR4 with EACA stretched (E), as turn (F), and merging
across multiple conformations of the ligand and protein according to Equation 11 (G).
Discussion
The very nature of large, flexible ligands, such as glycosaminoglycan chains, large receptor
loops, or novel supramolecular binders, makes it challenging to model their interactions
with proteins. First, these ligands are too large and flexible for small-molecule docking.
Even the notion of a well-defined binding pose, commonly used in small-molecule docking,
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probably has to be abandoned. Instead, we should restate the aim from finding the binding
pose to computing a probability density for the ligand around the protein. Second, the
vastness of their conformational space makes large, flexible ligands also difficult objects for
the standard method MD simulation, as it will be prone to severe undersampling.55,56 A
third established candidate method is continuum electrostatics. It takes advantage of the
charged nature of the ligands, but the electrostatic potential alone is difficult to interpret.
The fact that electrostatics alone is not sufficient to locate large charged ligands like DNA
or RNA has been noted before.57,58 Our results corroborate this because we found only a
weak correlation between the electrostatic potential, the probability density obtained from
extensive MD simulations of the Shh-heparin system, and corresponding experimental data.
In this case we achieved good consistency with MD simulation and experimental structures
with EGs that complement electrostatics with information about shape and volume of the
ligand or ligand fragments.
The good correlation of the EG approach with probability densities from extensive MD
simulations at a small fraction of the computational cost (typically CPU minutes vs. weeks)
makes EGs an interesting way to approximate such densities. However, there are also limi-
tations that should be considered. There are two basic categories of deficiencies: first, those
due to features of the real system that are missing in the model, and second, those due to
inadequate configuration of the model.
Intra-ligand interactions fall into the first category of deficiencies. In the fragment-
based screening used for the EGs, we neglect interactions between fragments. This can be
problematic since we are looking at large, flexible ligands that carry charges, and that can
have plenty of opportunities for such interactions, e.g. repulsion between same sign charges,
salt-bridges, or pi-cation interactions. It is clear that such interaction exist, and that they
can have an impact on the ligand structure.59 A factor that could limit the severity of the
effect of intra-molecular interactions is that they have to compete with ligand-protein and
ligand-water interactions, and with the conformational entropy of the ligand.
Another example of a principal deficiency of the underlying model is the use of continuum
electrostatics. This leads e.g. to the neglect of structural water molecules, although such
waters can be crucial for specific interactions at the surface of charged proteins.60,61 A similar
argument can be made for ions. Inclusion of fixed water molecules or ions in the protein
structure is technically feasible in EG computations. For a first tests we used the Trp
repressor interaction with a nucleotide ligand where structural water molecules are known
to mediate interactions.62 In this case the presence of the known structural water molecules
had a negligible effect on the ligand distribution (Figure S4).
Yet another deficiency is the treatment of molecular flexibility. In the case of the Kringle
domain we have demonstrated that flexibility can be included both on the side of the pro-
tein and the side of the ligand fragments. However, the relevant conformations have to be
known beforehand. If the protein-ligand interaction induces a new set of conformations, the
distributions obtained from the EGs may be misleading. While this has not been an issue
in the cases discussed above, it could be relevant for highly flexible or disordered proteins.
Finally, the FFT based correlation computation used in Epitopsy treats protein and lig-
and inconsistently: while the protein is modeled as uniform medium with a low dielectric
constant, the ligand is treated as point charges in continuum water. For flexible charged
ligands this approximation can be acceptable because they will be well-solvated and polar-
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izable, but it could become inaccurate for ligands with a more rigid structures or non-polar
regions.
The second category of deficiencies can be controlled by proper configuration of the
model. For instance, if the protein or the ligand fragment used for the computation of the
EG can assume several drastically different conformations and the user chooses only one
of those conformations, this will in general lead to systematic deviations between the com-
puted and true densities. This problem can be solved by inclusion of several conformations
(Equation 11).
Another source of errors that can be controlled is the grid configuration. If spatial or
angular grids are too coarse, regions around the protein that contribute to the EG will
be missed. In the present study we have used fragments with the maximum size of a di-
saccharide and a grid spacing of 0.8 Å, and the comparison with MD and experimental
data showed that the results are reasonable for the given ligands and proteins. However,
we expect that problems will arise with increasing ligand fragment size and ruggedness of
protein topography (Figure S5). For instance, the larger the ligand fragment and the deeper
protein pockets, the more difficult it will be to map the protein-ligand interaction on the
angular and spatial grid, because many fragment poses will lead to collisions and therefore be
discarded. Another useful parameter in this context is the clash penalty δ (Equation 1). A
weaker penalty will increase noise but has also the potential of making visible finer structures
in EG or probability density (Figure S3).
The correct charge of the ligand fragment is crucial, as shown in the epimerase example.
However, the approach is robust against small variations in the charge distribution (see
e.g. Figure S6), so that resource-intensive QM-based methods for charge assignment may be
substituted with MM forcefield charges.
An important point that has not been addressed in this work is heterogeneous ligand
composition. In the presented examples we could infer the location of larger ligands from
fragment probability densities because the large ligand had a rather homogeneous compo-
sition, e.g. it was a heparin poly-saccharide with negative charges on all di-saccharides, or
a multi-branched ligand with positively charged GCP and Lys groups. However, such large
ligands may comprise subunits of different physico-chemical characters. In this case infor-
mation of EGs for different ligand fragments have to be combined to infer likely locations
of complete ligands. We are currently developing methods to post-process sets of EGs for
heterogeneous ligands in this sense.
We have argued in the beginning that current computational methods are not suitable
for the treatment of large, flexible ligands or that their application is very expensive. Un-
fortunately, the same applies also to high-resolution experimental characterization by X-ray
crystallography or NMR. This makes it all the more important to develop reliable and effi-
cient computational methods that can e.g. be used to predict protein residues that are crucial
for the interaction with the ligand. Such predictions can then be tested e.g. by measuring
affinity changes after site-directed mutagenesis.
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